FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3191039731> ?p ?o ?g. }

• W3191039731 endingPage "108011" @default.
• W3191039731 startingPage "108011" @default.
• W3191039731 abstract "To identify which individual-, physician-, and the healthcare system-related factors can predict individualized hemoglobin A1c (HbA1c) targets and the likelihood of reaching those targets after initial insulin therapy over a two-year follow-up period. Real-world data, including baseline characteristics of people with type 2 diabetes mellitus (T2DM), psychosocial data, and diabetes medication use, collected from the Multinational Observational Study Assessing Insulin Use (MOSA1c) study in 18 countries were analyzed. Overall, 225 of 1194 people with T2DM (18.8%) who received initial insulin therapy for ≥3 months reached HbA1c targets at two-year follow-up; most were likely to be White (64.9%) and perceptions of their relationship with physicians were less positive than those who did not reach HbA1c targets. Higher baseline HbA1c (>8%) was the strongest predictor of being assigned an HbA1c target >7% (odds ratio [OR] 6.06, 95% confidence interval [CI] 3.97, 9.26). A smaller difference between baseline and target HbA1c levels was the strongest predictor of reaching an HbA1c target at two-year follow-up (large vs small difference, OR 0.28, 95% CI 0.17, 0.47). Several factors were significantly associated with establishing individualized HbA1c targets and reaching these targets. A small proportion of people with T2DM on insulin therapy reached their HbA1c target. Personalized management of glycemic targets necessitates the adoption of multi-factorial strategies, as several factors could influence an individual's glycemic outcome. NCT01400971 • This study sought to identify which individual, physician, and healthcare system-related factors can predict individualized HbA1c target levels and the likelihood of HbA1c target achievement after initial insulin therapy over a 2-year follow-up period. • Real-world data were collected from the prospective Multinational Observational Study Assessing Insulin use (MOSA1c) study over a 2-year follow-up period in 18 countries. • Of 1194 individuals with type 2 diabetes mellitus (T2DM) who received initial insulin therapy for ≥3 months and qualified for analysis, 225(18.8%) achieved their HbA1c targets at 2 years. • Personalized management of glycemic control necessitates the adoption of multi-factorial strategies, as several factors could influence the possibility of achieving established goals." @default.
• W3191039731 created "2021-08-16" @default.
• W3191039731 creator A5009318195 @default.
• W3191039731 creator A5013470862 @default.
• W3191039731 creator A5029675803 @default.
• W3191039731 creator A5049170609 @default.
• W3191039731 creator A5076825992 @default.
• W3191039731 creator A5077886706 @default.
• W3191039731 creator A5087640246 @default.
• W3191039731 date "2021-11-01" @default.
• W3191039731 modified "2023-10-01" @default.
• W3191039731 title "Individualized HbA1c target selection and achievement in the Multinational Observational Study Assessing Insulin Use (MOSA1c) type 2 diabetes study" @default.
• W3191039731 cites W172609984 @default.
• W3191039731 cites W1811210685 @default.
• W3191039731 cites W1994890616 @default.
• W3191039731 cites W2002726887 @default.
• W3191039731 cites W2020775602 @default.
• W3191039731 cites W2022069934 @default.
• W3191039731 cites W2028778815 @default.
• W3191039731 cites W2031542147 @default.
• W3191039731 cites W2033439452 @default.
• W3191039731 cites W2036591017 @default.
• W3191039731 cites W2052793098 @default.
• W3191039731 cites W2056930506 @default.
• W3191039731 cites W2057595002 @default.
• W3191039731 cites W2062010634 @default.
• W3191039731 cites W2070309137 @default.
• W3191039731 cites W2072793263 @default.
• W3191039731 cites W2079335866 @default.
• W3191039731 cites W2083972549 @default.
• W3191039731 cites W2110418106 @default.
• W3191039731 cites W2114369760 @default.
• W3191039731 cites W2118828750 @default.
• W3191039731 cites W2144611099 @default.
• W3191039731 cites W2165825148 @default.
• W3191039731 cites W2167578257 @default.
• W3191039731 cites W2167914620 @default.
• W3191039731 cites W2366221926 @default.
• W3191039731 cites W2465522410 @default.
• W3191039731 cites W2466978489 @default.
• W3191039731 cites W2517165909 @default.
• W3191039731 cites W2591702989 @default.
• W3191039731 cites W2594451671 @default.
• W3191039731 cites W2748858803 @default.
• W3191039731 cites W2795364426 @default.
• W3191039731 cites W2871057495 @default.
• W3191039731 cites W2917198334 @default.
• W3191039731 cites W2958831923 @default.
• W3191039731 cites W2991652243 @default.
• W3191039731 cites W2996732450 @default.
• W3191039731 cites W4236126199 @default.
• W3191039731 cites W4255037836 @default.
• W3191039731 doi "https://doi.org/10.1016/j.jdiacomp.2021.108011" @default.
• W3191039731 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34535360" @default.
• W3191039731 hasPublicationYear "2021" @default.
• W3191039731 type Work @default.
• W3191039731 sameAs 3191039731 @default.
• W3191039731 citedByCount "2" @default.
• W3191039731 countsByYear W31910397312022 @default.
• W3191039731 countsByYear W31910397312023 @default.
• W3191039731 crossrefType "journal-article" @default.
• W3191039731 hasAuthorship W3191039731A5009318195 @default.
• W3191039731 hasAuthorship W3191039731A5013470862 @default.
• W3191039731 hasAuthorship W3191039731A5029675803 @default.
• W3191039731 hasAuthorship W3191039731A5049170609 @default.
• W3191039731 hasAuthorship W3191039731A5076825992 @default.
• W3191039731 hasAuthorship W3191039731A5077886706 @default.
• W3191039731 hasAuthorship W3191039731A5087640246 @default.
• W3191039731 hasConcept C118552586 @default.
• W3191039731 hasConcept C126322002 @default.
• W3191039731 hasConcept C134018914 @default.
• W3191039731 hasConcept C150966472 @default.
• W3191039731 hasConcept C156957248 @default.
• W3191039731 hasConcept C23131810 @default.
• W3191039731 hasConcept C2777180221 @default.
• W3191039731 hasConcept C2779306644 @default.
• W3191039731 hasConcept C2780473172 @default.
• W3191039731 hasConcept C44249647 @default.
• W3191039731 hasConcept C555293320 @default.
• W3191039731 hasConcept C71924100 @default.
• W3191039731 hasConceptScore W3191039731C118552586 @default.
• W3191039731 hasConceptScore W3191039731C126322002 @default.
• W3191039731 hasConceptScore W3191039731C134018914 @default.
• W3191039731 hasConceptScore W3191039731C150966472 @default.
• W3191039731 hasConceptScore W3191039731C156957248 @default.
• W3191039731 hasConceptScore W3191039731C23131810 @default.
• W3191039731 hasConceptScore W3191039731C2777180221 @default.
• W3191039731 hasConceptScore W3191039731C2779306644 @default.
• W3191039731 hasConceptScore W3191039731C2780473172 @default.
• W3191039731 hasConceptScore W3191039731C44249647 @default.
• W3191039731 hasConceptScore W3191039731C555293320 @default.
• W3191039731 hasConceptScore W3191039731C71924100 @default.
• W3191039731 hasFunder F4320307758 @default.
• W3191039731 hasIssue "11" @default.
• W3191039731 hasLocation W31910397311 @default.
• W3191039731 hasLocation W31910397312 @default.
• W3191039731 hasOpenAccess W3191039731 @default.
• W3191039731 hasPrimaryLocation W31910397311 @default.

• next